Susquehanna International Group, LLP Magenta Therapeutics, Inc. Transaction History

Susquehanna International Group, LLP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.62 - $0.79 $48,484 - $61,778	-78,201 Reduced 43.09%	103,302 $78,000
Q1 2023 May 16, 2023	BUY	$0.41 - $0.86 $74,416 - $156,092	181,503 New	181,503 $143,000
Q2 2022 Aug 15, 2022	BUY	$0.97 - $3.08 $44,588 - $141,581	45,968 New	45,968 $55,000
Q1 2022 May 16, 2022	SELL	$2.55 - $5.23 $26,609 - $54,575	-10,435 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.43 - $8.33 $46,227 - $86,923	10,435 New	10,435 $46,000
Q3 2021 Nov 15, 2021	SELL	$6.07 - $9.89 $125,042 - $203,734	-20,600 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$9.76 - $14.15 $62,102 - $90,036	-6,363 Reduced 23.6%	20,600 $201,000
Q1 2021 May 17, 2021	BUY	$7.66 - $13.38 $95,052 - $166,032	12,409 Added 85.26%	26,963 $319,000
Q4 2020 Feb 16, 2021	SELL	$6.1 - $7.94 $28,218 - $36,730	-4,626 Reduced 24.12%	14,554 $114,000
Q3 2020 Nov 16, 2020	BUY	$6.52 - $8.94 $125,053 - $171,469	19,180 New	19,180 $130,000
Q4 2019 Feb 14, 2020	SELL	$9.07 - $15.84 $96,287 - $168,157	-10,616 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$9.63 - $14.0 $102,232 - $148,624	10,616 New	10,616 $109,000

442K

Ticker MGTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,890,500
Description
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that ca...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.